This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Safety, Efficacy, Dose-finding Study of a Monoclonal Antibody in Patients With Multiple Myeloma

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT00231166
First received: September 30, 2005
Last updated: March 27, 2017
Last verified: March 2017
  Purpose
The purpose of this study is to determine the highest tolerated dose, safety and activity of HCD122 in patients with Multiple Myeloma who are relapsed after receiving prior treatment.

Condition Intervention Phase
Multiple Myeloma Drug: HCD122 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: A Phase I, Dose-finding Trial of HCD122, an Anti-CD40 Monoclonal Antibody, in Patients With Multiple Myeloma That is Relapsed or Has Not Responded to Prior Therapy (CHIR1212-C12101)

Resource links provided by NLM:


Further study details as provided by Novartis ( Novartis Pharmaceuticals ):

Primary Outcome Measures:
  • Safety, pharmacokinetics and pharmacodynamics at multiple doses [ Time Frame: At the completion of each dose escalation cohort ]

Secondary Outcome Measures:
  • Clinical response after various doses [ Time Frame: Once a month ]

Enrollment: 33
Study Start Date: September 2005
Study Completion Date: May 2009
Primary Completion Date: May 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: HCD122 Drug: HCD122

  Eligibility

Ages Eligible for Study:   18 Years to 100 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Clinical Diagnosis of MM requiring treatment
  • Refractory or Relapsed Disease
  • At least one prior treatment regimen
  • Male or Female
  • >18 years of age

Exclusion Criteria:

  • Prior Allogeneic bone marrow transplant (prior autologous transplant allowed)
  • Intracranial disease or epidural disease
  • Clinically significant cardiac dysfunction or other significant organ dysfunction
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00231166

Locations
United States, Massachusetts
Dana Farber Cancer Institute StudyCoordinator:CHCD122A2102
Boston, Massachusetts, United States, 02115
United States, New York
St. Vincent's Comprehensive Cancer Center Dept. of St. Vincent's Cancer
New York, New York, United States, 10011
United States, Oregon
Oregon Health Sciences University
Portland, Oregon, United States, 97239
United States, Pennsylvania
University of Pennsylvania--Abramson Cancer Center StudyCoordinator:CHCD122A2102
Philadelphia, Pennsylvania, United States, 19104
United States, Washington
Fred Hutchinson Cancer Research Center Dept. of FHCRC
Seattle, Washington, United States, 98109
Australia, Queensland
Novartis Investigative Site
Herston, Queensland, Australia, 4029
Australia, Victoria
Novartis Investigative Site
Prahran, Victoria, Australia, 3181
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
Study Director: Novartis Pharmaceuticals Novartis Pharmeceuticals
  More Information

Additional Information:
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00231166     History of Changes
Obsolete Identifiers: NCT00304109
Other Study ID Numbers: CHCD122A2102
Study First Received: September 30, 2005
Last Updated: March 27, 2017

Keywords provided by Novartis ( Novartis Pharmaceuticals ):
dose-finding
monoclonal antibody
Multiple Myeloma

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Antibodies, Monoclonal
Antibodies
Immunoglobulins
Immunologic Factors
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on June 27, 2017